Latent TGF-β binding protein LTBP-2 decreases fibroblast adhesion to fibronectin

Marko Hyytiäinen and Jorma Keski-Oja

Departments of Virology and Pathology, The Haartman Institute and Helsinki University Hospital, University of Helsinki, Helsinki FIN-00014, Finland

We have analyzed the effects of latent TGF-β binding protein 2 (LTBP-2) and its fragments on lung fibroblast adhesion. Quantitative cell adhesion assays indicated that fibroblasts do not adhere to full-length LTBP-2. Interestingly, LTBP-2 had dominant disrupting effects on the morphology of fibroblasts adhering to fibronectin (FN). Fibroblasts plated on LTBP-2 and FN substrate exhibited less adherent morphology and displayed clearly decreased actin stress fibers than cells plated on FN. These cells formed, instead, extensive membrane ruffles. LTBP-2 had no effects on cells adhering to collagen type I. Fibroblasts adhered weakly to the NH$_2$-terminal fragment of LTBP-2. Unlike FN, this fragment did not augment actin stress fiber formation. Interestingly, the adhesion-mediating and cytoskeleton-disrupting effects were localized to the same NH$_2$-terminal proline-rich region of LTBP-2. LTBP-2 and its antiadhesive fragment bound to FN in vitro, and the anti-adhesive fragment associated with the extracellular matrix FN fibrils. These observations reveal a potentially important role for LTBP-2 as an antiadhesive matrix component.

Introduction

Latent TGF-β binding protein 2 (LTBP-2) belongs to the LTBP–fibrillin gene family, which contains LTBPs 1–4 and fibrillins 1, 2 (Saharinen et al., 1999), and 3 (Genbank/EMBL/DDBJ accession no. AY165864). These proteins are ECM glycoproteins sharing similar overall domain structure. They consist mainly of cysteine-rich EGF-like and 8-cysteine (8-Cys) repeats. EGF-like repeats exist in a number of ECM proteins, whereas 8-Cys repeats have so far only been found in fibrillins and LTBP2s. Cysteine-rich regions are frequently interrupted by variable proline-rich regions in LTBP2s, while fibrillins contain only one such region.

Fibrillins were first identified as components of elastic tissue microfibrils. Microfibrils consist, in addition to fibrillins, of several other proteins like microfibril-associated glycoproteins (MAGPs) 1 and 2 (Rosenbloom et al., 1993). Fibrillins are important for the structure of microfibrils, as shown by mice expressing mutated fibrillin-1 forms (Pereira et al., 1997; Kiely et al., 1998; Gayraud et al., 2000). TGF-βs are secreted from cells as latent complexes composed of the mature dimeric growth factor together with its NH$_2$-terminal latency-associated peptide (Saharinen et al., 1999; Annes et al., 2003). The secretion of small latent (SL) TGF-β from the cells is augmented by LTBP-1 (Miyazono et al., 1991), and LTBP-1 directs this complex to the ECM (Taipale et al., 1994). At least LTBP-1 has a role in the activation of latent TGF-β (Flaumenhaft et al., 1993). LTBP-1 localizes to the fibrillin-containing ECM microfibrils as well as to the pericellular cell surface–associated fibronectin (FN) fibrils (Taipale et al., 1996; Isogai et al., 2003). The majority of LTBP-1 protein is secreted from the cells without SL-TGF-β (Taipale et al., 1994), suggesting that LTBP-1 has novel functions, like structural roles in the ECM.

After the identification of LTBP-1 (Kanzaki et al., 1990), three other LTBP2s have been cloned, namely LTBP-2, -3, and -4 (Moren et al., 1994; Yin et al., 1995; Giltay et al., 1997; Saharinen et al., 1998). LTBP-2 has been localized by immunoelectron microscopy to the elastic microfibrils in bovine tissues (Gibson et al., 1995). While LTBP-1, -3, and -4 are true SL-TGF-β binding proteins, LTBP-2 is unable to bind SL-TGF-β (Saharinen and Keski-Oja, 2000). In addition, gene-targeted mice for LTBP-2 show early embryonic lethality (Shipley et al., 2000) differing from the phenotypes of all TGF-β (TGF-β1, -β2, and -β3) gene knockout mice (Shull et al., 1992; Proetz et al., 1995).
Sanford et al., 1997). This indicates that at least LTBP-2 has important functions not related to TGF-β.

Cell interactions with ECM components are a central, regulated cascade of events both during embryo- and organogenesis and during later stages of life (Gumbiner, 1996). Cells adhere to the ECM via cell surface receptors, often via integrin receptors and RGD recognition sequences of ECM proteins (Ruoslathi, 1996). FN (Vaheri and Ruoslathi, 1975) is the most widely studied example of an adhesive ECM component. Earlier studies indicated that LTBP-2–associated ECM components, such as fibrillin-1 and MAGP-2, mediate cell adhesion, at least in part via their RGD sequences (Sakamoto et al., 1996; Gibson et al., 1999). LTBP-2 contains an RGD cell adhesion sequence, which led us to explore the possible adhesive functions of LTBP-2 for human lung fibroblasts. We chose lung fibroblasts for our studies because lung is the major site of LTBP-2 expression (Moren et al., 1994). These cells attached to a specific proline-rich NH₂-terminal fragment of LTBP-2, which did not, however, contain the RGD sequence. Fibroblasts adhering to this fragment did not spread appreciably or form actin stress fibers. In contrast, this fragment exhibited a dominant cytoskeleton formation–disrupting effect on fibroblasts. LTBP-2 and especially its proline-rich NH₂-terminal region exerted modulatory effects on the actin cytoskeleton of fibroblasts and induced a less adherent phenotype. LTBP-2 is thus a new member to the family of extracellular antiadhesive glycoproteins.

Results
Production of LTBP-2 fragments
To explore the effects of LTBP-2 and its domains on cell adhesion, we produced partially overlapping recombinant protein fragments covering the whole LTBP-2 protein (Fig. 1 A). The fragments were expressed either as histidine-tagged fragments or as dimeric fusion proteins with the constant region of immunoglobulin G to aid purification. The reason for using the Ig tag was that the expression levels were generally higher, and some fragments were more soluble when expressed as fusion proteins with a relatively large IgG constant region than those with a small histidine tag (not depicted). However, all the results obtained with Ig-tagged proteins were confirmed with histidine-tagged fragments.

All protein fragments were secreted from the cells, but the expression levels varied. The larger fragments were, in general, expressed at lower levels than the smaller ones. Some proteins were prone to proteolysis by endogenous proteases. This was noted with fragments containing the proline-rich regions before the hybrid domain (fragments L2-IV, L2-VII), and especially with COOH-terminal fragments containing the proline-rich region (fragments L2-XII and L2-XIV) (Fig. 1 B), suggesting that the COOH terminus of LTBP-2 is sensitive to proteases in intact, full-length protein. A related cleavage has been described earlier with corresponding LTBP-1 fragments (Unsöld et al., 2001). Fragment L2-X containing the previously identified protease-sensitive area (Hyryläinen et al., 1998) was also slightly degraded. The migration of fragment L2-X was also anomalous in SDS-PAGE. The calculated molecular mass of this dimeric fragment L2-X together with the Ig tag is \(~\)80 kD, but it migrated as an almost 200-kD band. The reason for its aberrant migration in SDS-PAGE is unclear at present.

The histidine-tagged LTBP-2 fragments were purified by metal chelate chromatography as described above. In addition to the fragments, there was occasionally an \(~\)65-kD contaminating protein, which copurified from CHO-conditioned medium in metal chelate chromatography (Fig. 1 B, lane L2-N*). It could be removed with gel filtration and was
Antiadhesive properties of LTBP-2

Hyytiäinen and Keski-Oja 1365

not responsible for the cell adhesion effects of the LTBP-2 fragments (not depicted).

Lung fibroblasts bind to an NH$_2$-terminal fragment of LTBP-2

As LTBP-2 has a potential cell adhesion–mediating RGD sequence (Fig. 1 A) (Ruoslaiti, 1996), we analyzed first the properties of LTBP-2 and its recombinant fragments in cell adhesion assays (Fig. 2 A) using FN as a control. Full-length LTBP-2 did not display significant effects in the cell binding assays with any of the coating concentrations used (Fig. 2 A and not depicted). Unexpectedly, fibroblasts adhered to fragment L2-IV, which contains the hybrid domain and the preceding proline-rich area (illustrated in Fig. 1). The number of cells attaching to wells coated with this fragment was constantly lower than that attached to FN-coated wells (maximally ~60% of the binding to FN).

To localize more exactly the fibroblast-binding region of LTBP-2, we constructed and expressed two new Ig fusion proteins, L2-V and L2-VI, covering the proline-rich variable region before the hybrid domain, and the hybrid domain, respectively. Cell culture plates were then coated with these fragments, and cell adhesion assays were performed as described in the previous section (Fig. 2 B). The cells adhered to the wells coated with fragment L2-V in a concentration-dependent manner, whereas no adhesion to fragment L2-VI (containing the hybrid domain) was observed.

To confirm the results and to rule out the possibility that the adherence would be caused by artificial dimer formation of Ig fusion proteins, we expressed, purified, and repeated the adhesion assays with histidine-tagged fragments of LTBP-2 (Fig. 3). Two NH$_2$-terminal fragments were produced, a larger one, covering most of the NH$_2$-terminal half of LTBP-2 (L2-N*), and a short one (L2-V*), corresponding to fragment L2-V. As expected, lung fibroblasts adhered to both fragments in a concentration-dependent manner. The fragments exhibited bell-shaped dose-
response effects: after reaching a critical coating concentration, cell adhesion decreased.

**NH₂-terminal fragments of LTBP-2 induce modest cell spreading, but not actin stress fiber formation**

To characterize the effects of the fibroblast adhesion–mediating LTBP-2 fragments on cell morphology, we visualized actin cytoskeletons with fluorescently labeled phalloidin after plating the cells on coverslips coated with LTBP-2 or its fragments (Fig. 4 A) and quantified cell spreading on these substrates (Fig. 4 B). The coating concentrations of fragments were chosen for optimal cell binding as analyzed in Fig. 3. Cells seeded on BSA-coated coverslips spread very poorly and did not form stress fibers. Cells seeded on full-length LTBP-2 spread even less (Fig. 4 B). Filamentous actin localized to patches in the cytoplasm, but no distinct structures could be observed. Even lower concentrations of LTBP-2 did not induce cell spreading (not depicted). Cells plated on coverslips coated with NH₂-terminal LTBP-2 fragments spread slightly more, but significantly less than on FN (Fig. 4 B). Phalloidin staining was partially localized to the cytoplasm, but also to the membrane ruffles in the cell periphery (Fig. 4 A). Cells attached to LTBP-2 fragments did not form actin stress fibers.

**LTBP-2 and its fragments have dominant actin cytoskeleton and focal adhesion–disrupting effects in fibroblasts adhering to FN**

To analyze whether LTBP-2 or its fragments can affect cell adhesion and actin cytoskeleton organization in cells adhering to FN, we performed quantitative adhesion assays and phalloidin stainings as above. In preliminary experiments, we noted that simultaneous coating of the plates with both proteins at the concentrations used decreased the coating efficiency of FN. This was determined by semiquantitative immunoblotting analysis of coverslip/cell culture plate-bound FN (unpublished data). To maintain constant levels of coverslip-bound FN, the coverslips were first coated with FN and the binding sites were saturated with BSA. Subsequently, the indicated LTBP-2 fragments were allowed to bind onto coverslips in PBS. Due to this sequence in coating, only the effects of the proteins bound either to FN or nonspecifically to BSA were detected in the attachment assays (Fig. 5). We found that full-length LTBP-2 bound nonspecifically to all coverslips and plates under these coating conditions, even to BSA (not depicted).

Full-length LTBP-2 had a relatively minor effect (about 10% decrease) on the number of cells adhering to FN substratum (Fig. 5 A), and statistical values were *P > 0.05*, when cell adhesion was compared with cells adhering to FN. As LTBP-2 proved later to have antiadhesive effects (see next paragraph), we compared its effects to tenascin-C, a known anti-

![Figure 4](https://example.com/figure4.png)
adhesive protein (Chiquet-Ehrismann et al., 1988; Huang et al., 2001). The effects of tenasin-C were of the same magnitude as those of LTBP-2.

Next, we investigated the effects of LTBP-2 on actin cytoskeletons of cells attaching to FN. Full-length LTBP-2 and its NH₂-terminal fragments had a dominant actin stress fiber formation–disrupting effect on fibroblasts when compared with cells plated on FN alone (Fig. 5 B). Actin staining was mainly localized to the cell periphery, including membrane ruffles and patch-like structures at the extremities of the cells, resembling very much the cells plated on LTBP-2 fragments only (compare with Fig. 4), whereas cells plated on FN formed extensive stress fibers. The effect resembled that of tenasin-C. In addition, cells cultured on LTBP-2/FN substratum were less spread than control cells (Fig. 6 A). The COOH-terminal control fragment L3-C* derived from LTBP-3 (Penttinen et al., 2002) did not exhibit any detectable effects on cell morphology or actin cytoskeleton formation (Fig. 5 B).

Focal adhesions are another important cellular structure for cell adhesion. We explored the effects of LTBP-2 on focal adhesions of cells adhering to FN by localizing two well-characterized focal adhesion proteins, vinculin and paxillin (Petit and Thiery, 2000). Focal adhesions formed efficiently in cells adhering to FN substratum (Fig. 5 C, left). In contrast, focal adhesion formation was disrupted by LTBP-2 (Fig. 5 C, right). Vinculin and paxillin were mostly cytoplasmic, and no distinct structures could be observed. A small portion of the
staining was in the tips of the cell extensions and membrane ruffles in a manner similar to actin staining. These findings further support the hypothesis that LTBP-2 acts as an antiadhesive protein that decreases fibroblast adhesion.

**Antiadhesive effect of LTBP-2 is concentration dependent**

We explored next the concentration dependency of the antiadhesive effect of LTBP-2. Glass coverslips were coated with a constant concentration of FN (10 µg/ml). Nonspecific binding sites were saturated with BSA, and the coverslips were incubated with increasing concentrations of LTBP-2 or its fragments L2-N* and L2-V*. Fibroblasts plated on BSA only served as a control. Fibroblasts were fixed 90 min after plating and stained for actin. Cells lost their adherent morphology when the concentrations of LTBP-2 or its fragments were increased. Bottom, quantification of cell spreading. Cell spreading was quantified from the coverslips (three independent fields). Note the differences in maximal effects of LTBP-2 and its fragments. (B) Comparison of LTBP-2 and tenascin-C effects on actin stress fiber formation. Actin stress fiber formation of cells was quantified from coverslips treated with increasing concentrations of LTBP-2 or tenascin-C.
coated substratum. These effects were similar to those obtained by using tenascin-C (Fig. 6 B and not depicted). The fragments L2-N* and L2-V* had quite similar concentration-dependent effects on cell morphology and actin cytoskeleton organization. However, the actin cytoskeleton– and cell spreading–disrupting effects were less efficient than with full-length LTBP-2 (Fig. 6 A). Unlike LTBP-2 itself, the fragments reached a saturating concentration. The increase of the coating concentration over a certain limit (2.5 μg/ml with L2-N* and 1.25 μg/ml with L2-V*) did not further inhibit cell spreading or prevent further actin cytoskeleton organization (compare with LTBP-2 panel).

LTBP-2 and its antiadhesive fragments bind to FN
To gain an insight into the mechanisms of the antiadhesive property, we analyzed whether LTBP-2 or its antiadhesive fragments could bind directly to FN or collagen type I. For this purpose, we established an enzyme-linked immunosorbent assay. Plates of 96 wells were first coated with increasing concentrations of FN or collagen type I. Both proteins coated the plates effectively under these conditions. Soluble LTBP-2 or its fragments were then incubated in the wells in a buffer containing BSA to prevent binding of LTBP-2 to BSA. Bound LTBP-2 was detected with polyclonal affinity-purified antibodies, and histidine-tagged fragments were detected with monoclonal antibody recognizing the histidine tag (Fig. 7 A). We observed that LTBP-2 and its fragments L2-N* and L2-N* bound to FN in a concentration-dependent and saturable manner, showing the specificity of binding (Fig. 7). In contrast, no binding of LTBP-2 to collagen type I was observed.

LTBP-2 fragment L2-V* associates with the ECM
To analyze the extracellular localization of the NH$_2$-terminal antiadhesive fragments in overexpressing cells, we transfected COS-7 cells and detected the expressed proteins by indirect immunofluorescence using antibodies recognizing the histidine tag. Secreted and either cell surface– or ECM-bound histidine-tagged fragments (Fig. 8) were detected in nonpermeated cells. To detect possible colocalization with LTBP-2 fragments, we performed FN immunofluorescence analysis of the same cells.

An antibody recognizing the histidine tag gave only faint background staining in nontransfected control COS-7 cells (Fig. 8, no transfection). The long fragment L2-N* localized clearly to ECM fibers, colocalizing with FN. Part of the staining localized to the surface of cells (Fig. 8, L2-N*). Several ECM binding regions have been localized to the corresponding NH$_2$-terminal region of LTBP-1 (Nunes et al., 1997; Unsold et al., 2001), and this pattern was therefore expected.

The antiadhesive fragment L2-V* localized to the extracellular/pericellular matrix as well (Fig. 8, L2-V*). The staining was more discontinuous than that of fragment L2-N*. The staining clearly colocalized with FN in many, but not all, locations.

Histidine-tagged fragment L2-X* was used as a control. This fragment was detected at the surfaces of the cells (Fig. 8, L2-X*), and no obvious colocalization with FN was detected.

COS-7 cells form relatively sparse extracellular matrices. We have therefore repeated the assays using human lung fi-

broblasts. The results were similar (unpublished data), but the transfection efficiencies of fibroblasts were very poor, which prevented their use in the assays.

LTBP-2 is not antiadhesive for cells adhering to type I collagen
We determined next whether the actin cytoskeleton–disrupting effect of LTBP-2 would be specific for FN. For this purpose, we coated coverslips with FN or collagen type I. Fibroblasts adhered more avidly to collagen type I than FN...
(unpublished data), permitting the use of lower concentrations of it (Fig. 9). After saturation of nonspecific binding sites with BSA, the coverslips were incubated with LTBP-2. Under these conditions, LTBP-2 bound to both types of coverslips, coated either with FN or collagen type I (not depicted). However, in the presence of LTBP-2, the cells adhering to FN were clearly less adherent and more rounded, whereas LTBP-2 had no appreciable effects on cells adhering to collagen type I (Fig. 9). We analyzed a wide range of FN and collagen type I coating concentrations in the assays. The effects of LTBP-2 on cells adhering to FN were always prominent, whereas effects on cells adhering to collagen type I were negligible (unpublished data). These results indicated that even though LTBP-2 is present on coverslips coated with both FN and collagen type I, the cytoskeleton-disrupting effect of LTBP-2 is effective only for cells adhering to FN.

Discussion

LTBP's have generally been considered proteins that target the effects of TGF-β by augmenting its secretion from the cells and targeting the latent complexes to appropriate sites in the ECM (Saharinen et al., 1999). So far relatively few other functions have been identified for LTBP's.

Fibrillins and other microfibril components, MAGP-2 (Gibson et al., 1999; Bax et al., 2003), mediate cell adhesion via RGD sequences. Fibrillin-1 seems to mediate cell adhesion also via non-RGD–dependent ways (Sakamoto et al., 1996). LTBP-2 possesses a putative cell adhesion–mediating RGD sequence, which led us to examine the effects of LTBP-2, and especially its NH$_2$ terminus, on cell adhesion.

Although full-length LTBP-2 did not mediate cell adhesion, we found with Ig-tagged fragments an area that supported fibroblast binding in cell adhesion assays. This activity was localized to the NH$_2$ terminus of LTBP-2 at the variable region toward the COOH terminus from the second EGF-like repeat and toward the NH$_2$ terminus from the hybrid domain. This region is rich in proline and positively charged amino acids and has no defined domain properties. The RGD sequence is not located at this area. When reanalyzing the results with histidine-tagged fragments, we observed that cell adhesion to plates coated with recombinant fragments of this region did not induce actin stress fiber formation, even though the cells spread slightly more efficiently.
than cells attaching onto BSA-coated coverslips. Actin was localized in these cells to membrane ruffles. In addition, we found that this region of LTBP-2 exhibited a concentration-dependent, bell-shaped effect on cell adhesion. This suggested that LTBP-2 might have antiadhesive properties and guided us to explore possible combinatorial effects of LTBP-2 and the adhesive ECM components FN and type I collagen on cell adhesion and morphology.

We found that full-length LTBP-2, its NH₂-terminal half, and the proline-rich region (fragment L2-V) had dramatic and dominant effects on the morphology of cells adhering to FN. Both LTBP-2 and its NH₂-terminal fragments prevented stress fiber formation and caused actin redistribution to the cell periphery. Cell spreading was also slightly impaired, and the cells were more rounded, contributing to a less adherent morphology. Accordingly, LTBP-2 disrupted focal adhesion formation. Paxillin and vinculin, proteins localizing normally to focal adhesions in adherent cells, localized mostly to patchy structures in the cytoplasm and partially to membrane ruffles in the presence of LTBP-2. Although the effect of LTBP-2 on the number of attaching cells was minor, the cytoskeletal changes were comparable to the other antiadhesive proteins such as SPARC (Sage et al., 1989) and thrombospondin (Murphy-Ullrich and Höök, 1989). This justifies the usage of the term antiadhesive with LTBP-2.

The effect was characteristic of FN; cells adhering to type I collagen exhibited normal cell morphology and actin cytoskeletons in the presence of LTBP-2. The tested proteins comprise only a small number of adhesive ECM components, and it will be of interest to analyze whether the antiadhesive effect of LTBP-2 is specific for example for certain integrins.

To obtain mechanistic insights for the antiadhesive effect of LTBP-2, we established a binding assay for LTBP-2. We noted that LTBP-2 binds to FN in a specific, saturable manner but not to type I collagen. In addition, in binding experiments with histidine-tagged fragments, we found that the fragments with antiadhesive properties bound to FN as well. Interestingly, the same fragments associated with the ECM and colocalized with FN in cell cultures.

In contrast to NH₂-terminal fragments, full-length LTBP-2 had no effects on cell adhesion, when coated separately. This fact suggests that the cell adhesive function is cryptic in full-length LTBP-2. However, FN-bound full-length LTBP-2 had antiadhesive effects on fibroblasts. We therefore propose that the binding of LTBP-2 to FN may result in exposure of cryptic, antiadhesive regions of LTBP-2.

We performed assays where we studied the concentration dependency of the antiadhesive effect of LTBP-2 and its fragments. Full-length LTBP-2 was the most effective in mediating antiadhesion, and the effects became more prominent when increasing the concentration of LTBP-2. In contrast, the fragments of LTBP-2 reached a saturation point. When increasing the coating concentration above a critical point, the effect was saturated. The maximal effects were not as drastic as with full-length LTBP-2. This effect may result from the saturation of LTBP-2 fragment binding sites in FN. LTBP-2 fragments may act by binding to FN (compare Figs. 6 and 7) and blocking some adhesive epitopes in FN. Full-length LTBP-2 may contain some additional binding sites/mechanisms for antiadhesion.

The above-mentioned observations suggest that LTBP-2 has an ability to bind to FN localized to ECM and mask its adhesive epitopes. Tenascin-C, a related antiadhesive ECM component, has been proposed to exert its effects via this mechanism. Tenascin-C binds FN and prevents syndecan-4 binding to it, causing a less adhesive phenotype in cells (Huang et al., 2001). Interestingly, the effects of tenascin-C were very similar to those of LTBP-2 in our studies. Major antiadhesive effects were observed as decreased stress fiber formation as well as cell spreading. Its effects on the number of attaching cells were minor. In studies by others (Huang et al., 2001) tenascin-C decreased the number of cells attaching to mixed tenascin-C/FN substratum. The noted difference possibly results from different experimental settings, such as the number of cells used in assays.

Fibroblasts were observed to bind to the antiadhesive fragment of LTBP-2. The morphology of the cells attaching to the fragments was strikingly similar to cells attaching to FN/ LTBP-2 substratum. This suggests that the cell-binding activity is related to its antiadhesive effect. Furthermore, the fact that cells bind to the antiadhesive fragment suggests that there might be a cell surface receptor recognizing this region of LTBP-2. This hypothetical cell surface component could act either in integrin adhesion complexes by sterically hindering integrin binding to its ligand, or alternatively as separate signaling receptors, affecting signal transduction and preventing integrin activation and cell adhesion. This kind of mechanism has been proposed for thrombospondin, another antiadhesive ECM protein. The NH₂-terminal fragment of thrombospondin binds to calreticulin at the cell surface, which affects the focal adhesion integrity (Goicoechea...
et al., 2000). However, so far we have not been able to detect such receptors.

We have observed recently that LTBP-2 acts as an adhesion protein for cultured melanoma cells (Vehviläinen et al., 2003). Melanoma cell adhesion leads to efficient cell spreading, and the actin cytoskeletons appeared comparable to cells adhered to FN. The adhesion was at least in part mediated by α5β1 and, to a lesser extent, α6β4 integrins. Interestingly, the melanoma cell adhesion site in LTBP-2 was localized to the same proline-rich fragment L2-V, which was antiadhesive for lung fibroblasts in the current study.

FN is a component of the so-called provisional matrices during development and wound healing (Mosher, 1995). We noted LTBP-2 to be antiadhesive of the tested ECM components only for cells adhering to FN. Therefore, it is possible that LTBP-2 has an antiadhesive role only for short periods of time during development when FN exists in ECM fibers. However, the antiadhesive role of LTBP-2 needs to be investigated in regard to the other adhesive ECM components.

Antiadhesion or counteradhesion is a relatively rare, but not extinct, phenomenon among ECM proteins (Chiquet-Ehrismann, 1995). Examples of antiadhesive proteins include thrombospondin, tenascin, and SPARC (BM-40). The modulation of cell adhesion is often related to cell migration. Filopodia and lamellipodia formation is crucial for cell movement, and the actin cytoskeleton plays an important role in these processes (Lauffenburger and Horwitz, 1996). As decreased actin stress fiber formation and increased membrane ruffle formation caused by LTBP-2 and its NH2-terminal fragment L2-V are consistent with the promotion of cell migration, it is tempting to speculate that the antiadhesive property of LTBP-2 is linked to the modulation of fibroblast migration in the lung and other tissues where LTBP-2 is expressed.

### Materials and methods

#### Cell culture

Human embryonic lung fibroblasts (CC-137; HEL-299, American Type Culture Collection) were maintained in MEM containing 10% fetal calf serum (Life Technologies, Inc.), 100 IU/ml penicillin, and 50 µg/ml streptomycin. CHO cells were maintained in MEM, 10% fetal calf serum supplemented with 0.2% BSA. Stable neomycin-resistant CHO clones were maintained in MEM containing 0.2% BSA, 10% fetal calf serum, penicillin/streptomycin, and 0.4 mg/ml G418 (Calbiochem). COS-7 cells were maintained in DME supplemented with penicillin/streptomycin and 10% fetal calf serum.

#### Fibroblast adhesion assays

Tissue culture 96-well plates were coated with LTBP-2 or its fragments at the concentrations indicated (50 µl/well) either at 4°C for 16 h, or at 20°C for 1 h in PBS (140 mM NaCl, 10 mM sodium phosphate, pH 7.4). Non-specific cell adhesion was prevented by incubating the wells with 100 µl of 20°C FCS (1 h) before the cell adhesion assay. The wells were washed with PBS before the adhesion assays. To detect the effects of LTBP-2 on cells adhering to FN or type 1 collagen, the tissue culture plates or glass coverslips were first coated with FN (10 µg/ml) or type 1 collagen (0.33 µg/ml). The proteins were prediluted with PBS at room temperature before coating. Non-specific binding sites were then saturated with heat-treated BSA as before. Coverslips or plates were then incubated with LTBP-2 (Hyttyläinen et al., 1998; Vehviläinen et al., 2003), its fragments, or recombinant tenascin-C (Fischer et al., 1997) (a gift of R. Chiquet-Ehrismann, Friedrich Miescher Institute, Basel, Switzerland) in PBS containing 1 mM CaCl2, 1 mM MgCl2 for 1 h. The plates were then washed twice with PBS containing 1 mM CaCl2, 1 mM MgCl2.

Cells were detached from plates with trypsin-EDTA and suspended into serum-free MEM. The cells were counted, spun down by centrifugation at 500 g for 5 min, and resuspended in serum-free medium (5 × 10^4 cells/ml). Aliquots of the cell suspension (100 µl; 5 × 10^4 cells) were plated in each well. The plates were incubated in a humidified incubator at 37°C for 1 h. Nonattached cells were removed by washing the wells twice with PBS. The cells were then fixed and stained by filtered 0.1% Coomassie blue dissolved in 30% methanol, 10% acetic acid. Subsequently, the cells were washed extensively with 30% methanol/10% acetic acid and once with PBS. The cells were lysed in 1% SDS, and A620 was measured. The results are presented as the mean value obtained from three different wells and compared with the data obtained from cell adhesion to FN. Error bars represent the standard error. Each experiment was performed at least three times.

#### Expression constructs

LTBP-2 fragments were expressed in stably transfected CHO cells as dimeric NH2-terminal fusion proteins with the Fc portion of immunoglobulin G as follows. Fragments of LTBP-2 cDNA were amplified by PCR using Pu1 or Pu2 Turbo polymerase (Stratagene) with primers designed to maintain the open reading frame after the signal sequence and to continue to Fc tail in signal plg1 (IRX Systems) vector. Primer sequences contained HindIII (5’ primers, all constructs except L2-X and BamHI (3’ primers, all constructs except L2-VII and L2-VIII) restriction enzyme recognition sites in the 5’ end of the primers. Construct L2-VII and L2-VIII 3’ primers contained NotI recognition sites, and construct L2-X 5’ primer contained KpnI recognition site. L2 constructs contained as a fusion partner amino acids of LTBP-2 as described and illustrated in Fig. 1 A. Antiadhesive property was determined according to the translated CDNA sequence in Genbank/EMBL/DDJB (accession no. Z37976). Control protein containing only the constant region of human IgG was obtained by expression of vector plg5+.

Histidine-tagged (six histidines) monomeric fragments were produced using psecTagA vector (Invitrogen). cDNA fragments were produced by PCR with the primers containing HindIII (5’) and NotI (3’) restriction enzyme recognition sites. L2-N* contains amino acids 161–843, L2-V* amino acids 429–550, and L2-X* amino acids 728–843 (also illustrated in Fig. 1 A).

PCR fragments were digested with the corresponding restriction enzymes and ligated to vector cut with the same enzymes. In constructs L2-VII and L2-VIII and psecTag constructs, adenosine nucleotides were first inserted into the 3′ ends of the PCR product with Tag polymerase, after which the PCR product was cloned into pGEM-T cloning vector (Promega), from which the fragment was cloned to the target vector. All constructs were sequenced to confirm that there were no PCR-derived mutations. Histidine-tagged human LTBP-3 COOH-terminal fragment L3-C* HL3/911–1153 was expressed and purified as described previously (Pentinen et al., 2002).

#### Expression and purification of LTBP-2 fragments

Stable neomycin-resistant CHO cell clones were obtained by transfecting the CHO cells with lipofectamine (Promega) with each expression construct as described earlier (Hyttyläinen et al., 1998). 1 d after transfection, the cells were changed to medium containing 1.5 mg/ml G418 (plg5+) or 0.5 mg/ml neomycin (psecTag), after which the cells were maintained in the selection medium for 2 wk. Stable drug-resistant cells were dilution cloned to 96-well plates, and the expression of fusion protein was estimated by dot blotting culture medium 1–2 wk after dilution cloning, using biotinylated protein A (Sigma-Aldrich) or penta-his monoclonal antibody (QIAGEN) as the first conjugate. The IgG fusion proteins were purified from the conditioned medium with protein A affinity chromatography.

Histidine-tagged proteins were first precipitated with 35% (NH4)2SO4. The precipitate was dissolved in the wash buffer (2 M urea, 300 mM NaCl, 50 mM Tris-HCl buffer, pH 7.2). The sample was loaded to Talon metal chelate (CLONTECH Laboratories, Inc.) column. The column was washed with the wash buffer, and the bound proteins were eluted with the same buffer containing 100 mM imidazole. The buffer of the fractions containing the fusion proteins was then exchanged using G50 and/or G10 columns with Fast Desalting column HR 10/10 (Amersham Biosciences).

#### Fluorescence staining of the cells

For the immunofluorescence detection of FN and histidine-tagged proteins in COS-7 cells, the cells were plated to six-well plates containing glass coverslips. After reaching semi-confluency, the cultures were transfected with the constructs expressing LTBP-2, as described and illustrated in the manufacturer’s instructions. Cells were then maintained in normal serum containing medium for 48 h before fixation. The transfected cultures were washed with PBS. The cells were then fixed with 3% paraformaldehyde for 15 min. The cells were washed three times with PBS at room temperature before coating. Non-specific binding sites were then saturated with heat-treated BSA as before. Coverslips or plates were then incubated with LTBP-2 or its fragments, its fragments, or recombinant tenascin-C (Fischer et al., 1997) (a gift of R. Chiquet-Ehrismann, Friedrich Miescher Institute, Basel, Switzerland) in PBS containing 1 mM CaCl2, 1 mM MgCl2 for 1 h. The plates were then washed twice with PBS containing 1 mM CaCl2, 1 mM MgCl2.
times with PBS, and nonspecific binding sites were saturated by incubating the cells with 5% BSA in PBS for 30 min. The coverslips were then treated simultaneously with perna-his monoclonal antibody (Qiagen) and anti-FN rabbit polyclonal antibodies (Sigma-Aldrich), followed by Texas red-conjugated anti-mouse secondary antibody and fluorescein isothiocyanate-conjugated anti–rabbit antibody (Jackson ImmunoResearch Laboratories). After washes, the coverslips were mounted with Vectashield (Vector Laboratories, Inc.).

For actin, vinculin, or phallolidin staining of CCL-117 fibroblasts, subconfluent cultures of cells were detached from tissue culture plates with trypsin-EDTA and washed with serum-free medium. The cells were resuspended in serum-free MEM, containing the indicated proteins, and plated onto acid-treated glass coverslips on six-well plate wells (10° cells/well). Coverslips were coated before plating as indicated in the Fibroblast adhesion assay sections. After 90 min, the medium was removed, and the cells were fixed with 3% paraformaldehyde in PBS for 20 min. The cells were permeated with 0.1% TX-100 in PBS for 5 min, and nonspecific staining was prevented by incubation with 5% BSA in PBS for 30 min. The cells were finally stained for filamentous actin with tetramethyl rhodamine isothiocyanate–conjugated phalloidin (Sigma-Aldrich) in PBS, 0.5% BSA. To detect vinculin, the cells were incubated with anti-vinculin monoclonal antibody (clone hVIN-1; Sigma-Aldrich), and to detect paxillin with antipaxillin monoclonal antibody (clone 349; BD Biosciences), and subsequently with Texas red-conjugated anti–mouse secondary antibody (Jackson ImmunoResearch Laboratories). After washes, the coverslips were mounted with Vectashield.

Coverslips were observed with an Axioplan 2 microscope (Carl Zeiss MicroImaging, Inc.) using 40× objective. Pictures were taken with AxioCam HR (Carl Zeiss MicroImaging, Inc.) digital camera and AxioVision 3.1 (Carl Zeiss MicroImaging, Inc.) software. Brightness and contrast of the images were adjusted with Corel Photo-Paint (Corel Inc.) and decorated with CorelDRAW (Corel Inc.) software.

Cell spreading and stress fiber quantification

Three independent and randomly chosen pictures were taken at 10× magnification from actin-stained cells. The cell spreading was determined by counting the area of each cell with the aid of Image-Pro software (Media Cybernetics). The average of >100 cells was calculated, and cell spreading on FN was set to one. The cell spreading values of cells on other substrates was then compared with this value. Cells in contact with other cells were excluded from the analysis. Actin stress fibers were quantified from similar pictures by manually counting the percentage of cells forming stress fibers on each substrate.

ELISA

Human plasma FN (Sigma-Aldrich) or native rat tail type I collagen (Upstate Biotechnology) were diluted from stock solutions in acetic acid to PBS to the indicated concentrations. Maxisorp 96-well plates (Nunc) were then coated with these proteins in PBS at 23°C for 1 h with shaking (as all subsequent steps). Nonspecific protein binding sites were saturated with 3% BSA in PBS (23°C, 1 h). Wells were then washed once with incubation buffer (PBS containing 1 mM CaCl₂, 1 mM MgCl₂, and 0.5% BSA). This buffer was used in all subsequent washes and incubations. Purified LTBP-2 or fragment L2-N² or L2-V² were diluted and incubated in the wells for 1 h. The wells were then washed twice with the incubation buffer (5 min each). Bound LTBP-2 was detect by incubating the wells with polyclonal affinity-purified antibody 11L2.2 for 1 h (Hyütänien et al., 1998). LTBP-2 fragments were detected with the perna-his monoclonal antibody. The plates were washed twice (5 min each) and incubated with anti-rabbit or anti–mouse horseradish peroxidase–conjugated secondary antibody for 30 min. The wells were finally washed (4 × 10 min) with the incubation buffer, and the bound immune complexes were detected with 1,2-phenylenediamine dihydrochloride (DakoCytomation) according to the manufacturer’s instructions. The reaction was terminated with H₂SO₄, and the color reactions were measured with a spectrophotometer at wavelength 450 nm.

We thank Dr. Antti Vaheeri for critical comments on the manuscript and Sami Starast for excellent technical assistance. We also thank Dr. Ruth Chiquet-Ehrismann for tenascin-C.

This study was supported by the Academy of Finland, Biocentrum Helsinki, Sigrid Juselius Foundation, Novo Nordisk Foundation, The Whihuri Foundation, Helsinki University Hospital Fund, Finnish Cancer Organizations, Oskar Oflund Foundation, Ida Montin Foundation, Biomedical Foundation, Research and Science Foundation of Farmos, The Finnish Cultural Foundation, and University of Helsinki.

Submitted: 17 September 2003
Accepted: 30 October 2003

References

Annes, J.P., J.S. Munger, and D.B. Räkin. 2003. Making sense of latent TGF-beta activation. J. Cell Sci. 116:217–224.

Bax, D.V., S.E. Bernard, A. Lomas, A. Morgan, J. Humphries, C.A. Shuttleworth, M.J. Humphries, and C.M. Kiely. 2003. Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alphaBeta1 and alphaBeta3 integrins. J. Biol. Chem. 278:34605–34616.

Chiquet-Ehrismann, R. 1995. Inhibition of cell adhesion by anti-molecular adhe-
sions. Curr. Opin. Cell Biol. 7:715–719.

Chiquet-Ehrismann, R., P. Kalla, C.A. Pearson, K. Beck, and M. Chiquet. 1988. Tenasin interferes with fibronectin action. Cell. 53:383–390.

Fischer, D., M. Brown-Ludi, T. Schulthess, and R. Chiquet-Ehrismann. 1997. Concerted action of tenasin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. J. Cell Sci. 110:1513–1522.

Flaumenhaft, R., M. Abe, Y. Sato, K. Miyazono, J. Harpel, C.H. Heldin, and D.B. Räkin. 1993. Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J. Cell Biol. 120:995–1002.

Gayraud, B., D.R. Keene, L.Y. Sakai, and F. Ramirez. 2000. New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin-1 mutation in the tight skin mouse. J. Cell Biol. 150:667–680.

Gibson, M.A., G. Hatzinikolas, E.C. Davis, E. Baker, G.R. Sutherland, and R.P. Mecham. 1995. Bovine latent transforming growth factor beta 1-binding protein 2: molecular cloning, identification of tissue isoforms, and immunolocalization to elastin-associated microfibrils. Mol. Cell. Biol. 15:6932–6942.

Gibson, M.A., D.J. Leavely, and L.K. Ashman. 1999. Microfibril-associated glycoprotein-2 specifically interacts with a range of bovine and human cell types via alphaV beta3 integrin. J. Biol. Chem. 274:13060–13065.

Giltay, R., G. Kostka, and R. Timpl. 1997. Sequence and expression of a novel member (LTBP-4) of the family of latent transforming growth factor-beta binding proteins. FEBS Lett. 411:164–168.

Goicoccoea, S., A.W. Orr, M.A. Pallero, P. Eggleton, and J.E. Murphy-Ullrich. 2000. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J. Biol. Chem. 275:36358–36368.

Gumbiner, B.M. 1996. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 84:345–357.

Huang, W., R. Chiquet-Ehrismann, J.V. Moyano, A. Garcia-Pardo, and G. Orend. 2001. Interference of tenasin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 61:8586–8594.

Hyütänien, M., J. Taipale, C.H. Heldin, and J. Keski-Oja. 1996. Reconstituent latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release. J. Biol. Chem. 273:20860–20867.

Isogai, Z., R.N. Ono, S. Ushiro, D.R. Keene, Y. Chen, R. Mazzieri, N.L. Chatbonneau, D.P. Reinhardt, D.B. Räkin, and L.Y. Sakai. 2003. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J. Biol. Chem. 278:2750–2757.

Kanzaki, T., A. Olofsson, A. Moren, C. Wennstedt, U. Hellman, K. Miyazono, L. Claesson-Welsh, and C.H. Heldin. 1990. TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell. 61:1091–1061.

Kiely, C.M., M. Raghunath, L.D. Stracca, M.J. Sherratt, R. Peters, C.A. Shuttleworth, and S.A. Jimenez. 1998. The tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J. Cell Biol. 140:1159–1166.

Lauffenburger, D.A., and A.F. Horwitz. 1996. Cell migration: a physically integrated molecular process. Cell. 84:359–369.

Miyazono, K., A. Olofsson, P. Colosetti, and C.H. Heldin. 1991. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10:1991–1101.

Moren, A.A., A. Olofsson, G. Stenman, P. Sahlin, T. Kanzaki, L. Claesson-Welsh, P. T. Dijke, K. Miyazono, and C.H. Heldin. 1994. Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J. Biol. Chem. 269:32469–32478.

Mosher, D.F. 1995. Organization of the provisional fibronectin matrix: control by products of blood coagulation. Thromb. Haemost. 74:529–533.

Murphy-Ullrich, J.E., and M. Hoök. 1989. Thrombospondin modulates focal ad-
hesions in endothelial cells. J. Cell Biol. 109:1309–1319.
Nunes, I., P.E. Gleizes, C.N. Metz, and D.B. Rifkin. 1997. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J. Cell Biol. 136:1151–1163.
Penttinen, C., J. Saharinen, K. Weikkolainen, M. Hyytiala, and J. Keski-Oja. 2002. Secretion of human latent TGF-beta-binding protein-3 (LTBP-3) is dependent on co-expression of TGF-beta. J. Cell Sci. 115:3457–3468.
Pereira, L., K. Andrikopoulos, J. Tian, S.Y. Lee, D.R. Keene, R. Ono, D.P. Reinhardt, J.Y. Sakai, N.J. Biery, T. Bunton, et al. 1997. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat. Genet. 17:218–222.
Petit, V., and J.P. Thiery. 2000. Focal adhesions: structure and dynamics. Biol. Cell. 92:477–494.
Proetzel, G., S.A. Pawlowski, M.V. Wiles, M. Yin, G.P. Boivin, P.N. Howles, J. Ding, M.W. Ferguson, and T. Doetschman. 1995. Transforming growth factor-beta3 is required for secondary palate fusion. Nat. Genet. 11:409–414.
Rosenbloom, J., W.R. Abrams, and R. Mecham. 1993. Extracellular matrix 4: the elastic fiber. FASEB J. 7:1208–1218.
Ruoslahti, E. 1996. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:697–715.
Sage, H., R.B. Vernon, S.E. Funk, E.A. Everitt, and J. Angello. 1989. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca2+-dependent binding to the extracellular matrix. J. Cell Biol. 109:341–356.
Saharinen, J., and J. Keski-Oja. 2000. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBP3s, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol. Biol. Cell. 11:2691–2704.
Saharinen, J., J. Taipale, O. Monni, and J. Keski-Oja. 1998. Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J. Biol. Chem. 273:18459–18469.
Saharinen, J., M. Hyytiainen, J. Taipale, and J. Keski-Oja. 1999. Latent transforming growth factor-beta binding proteins (LTBPs) - structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev. 10:99–117.
Sakamoto, H., T. Broekelmann, D.A. Cherosh, F. Ramirez, J. Rosenbloom, and R.P. Mecham. 1996. Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. J. Biol. Chem. 271:4916–4922.
Sanford, L.P., I. Ormsby, A.C. Gittenberger-de Groot, H. Sarriola, R. Friedman, G.P. Boivin, E.L. Cardell, and T. Doetschman. 1997. TGF-beta2 knockout mice have multiple developmental defects that are non-overlapping with other TGF-beta knockout phenotypes. Development. 124:2659–2670.
Shipley, J.M., R.P. Mecham, E. Maus, J. Bonaduo, J. Rosenbloom, B.T. McCarthy, M.L. Baumann, C. Frankai, F. Segade, and S.D. Shapiro. 2000. Developmental expression of latent transforming growth factor beta binding protein 2 and its requirement early in mouse development. Mol. Cell. Biol. 20:4879–4887.
Shull, M.M., I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 359:693–695.
Taipale, J., K. Miyazono, C.H. Heldin, and J. Keski-Oja. 1994. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J. Cell Biol. 124:171–181.
Taipale, J., J. Saharinen, K. Hedman, and J. Keski-Oja. 1996. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibris. J. Histochem. Cytchem. 44:875–889.
Unsöld, C., M. Hyytiainen, L. Bruckner-Tuderman, and J. Keski-Oja. 2001. Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J. Cell Sci. 114:187–197.
Vaheri, A., and E. Ruoslahti. 1975. Fibroblast surface antigen produced but not retained by virus-transformed human cells. J. Exp. Med. 142:530–535.
Vehviläinen, P., M. Hyytiala, and J. Keski-Oja. 2003. Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells. J. Biol. Chem. 278:24705–24713.
Yin, W., E. Smiley, J. Germiller, R.P. Mecham, J.B. Florer, R.J. Wennstrup, and J. Bonadio. 1995. Isolation of a novel latent transforming growth factor-beta binding protein gene (LTBP-3). J. Biol. Chem. 270:10147–10160.